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Abstract The vgfgene encodes one of the most rapidly induced 
neuronal mRNAs identified in NGF-treated PCI2 cells. Maximal 
inhibition of VGF mRNA induction was achieved using K-252a, 
an inhibitor of the NGF-receptor Trk tyrosine kinase, and by 
mutating both Y490 (SHC association site) and Y785 (PLC-yl 
association site) of Trk. Inhibitors of the NGF-activated protein 
kinase N (PKN) were found to partially and in some cases tran- 
siently block VGF induction by NGF while in PKA-deficient 
PC12 cells, VGF induction by NGF was comparable to that 
observed in parental PC12 cells. The binding of NGF to Trk 
therefore activates redundant signal transduction pathways which 
converge to regulate vgfgene expression. 
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1. Introduction 
In the presence of nerve growth factor (NGF) and basic 
fibroblast growth factor (bFGF) but not epidermal growth 
factor (EGF), PC 12 pheochromocytoma cells differentiate into 
sympathetic neuron-like cells [1 ]. Treatment of PC 12 cells with 
NGF results in the rapid tyrosine phosphorylation f multiple 
cellular proteins [2] and the stimulation of several second mes- 
senger pathways through the actions of a number of tyrosine 
and serine/threonine kinases [3]. The importance of protein 
phosphorylation in the mechanism of action of NGF has been 
reinforced by the identification of the product of the trk tyro- 
sine kinase protooncogene as the high affinity NGF receptor 
[4,5], and the demonstration that Trk is a necessary component 
of the NGF signaling pathway that is required for neurite 
outgrowth and the promotion of PC12 cell survival [6]. 
NGF-treatment stimulates p2 l"S GTP-binding activity, caus- 
ing prolonged p21 . . . . .  and ERK activation in comparison to 
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EGF, a growth factor which does not cause neuronal differen- 
tiation of PC12 cells [7]. Selective inhibition of protein kinase 
activity through the application of purine analogs inhibits 
NGF-promoted neurite regeneration and the NGF-regulated 
serine/threonine protein kinase N (PKN) but does not block 
several other effects of NGF [8 10] suggesting that the develop- 
ment and maintenance of a neuronal phenotype results from 
the complex regulation of a number of protein kinases. Insight 
into the process of neuronal differentiation may be obtained 
through study of gene products uch as VGF [11] which are 
rapidly activated more robustly by NGF than by EGF, in 
contrast to transcripts of the immediate early genes c-fos, c-jun, 
and zoe268 (NGFI-A), which appear to be induced similarly by 
either NGF, EGF, or serum stimulation [12]. In PC12 cells, 
VGF mRNA levels increase at least 15 30-fold after 3-6 h of 
NGF treatment and return to basal evels after approximately 
48 h [13,14]. Induction of vgf gene expression is mimicked by 
activation of a Src-Ras-Raf cascade in PC12 cells [15], and is 
partially blocked by protein synthesis inhibitors [16,17] and 
downregulation of protein kinase C (PKC)-dependent path- 
ways [14]. Here we utilize a number of protein kinase inhibitors, 
several PC 12-derived cell lines that express wild type or mutant 
forms of Trk, and a PKA-deficient PC12 cell line to character- 
ize the relative contributions of specific signal transduction 
pathways to the regulation of vgf gene expression by NGF. 
2. Materials and methods 
2.1. Cell culture 
PC 12 cells, PC 12nnr5 cell ines expressing wild type and mutant Trks 
(generously provided by Dr. L.A. Greene), and PC12 variant A126- 
1B2 cells (kindly provided by Dr. J.A. Wagner) were grown on colla- 
gen-coated dishes [1]. Purine analogs were added to cultures from 
concentrated stocks as described [18]. Where specified, PC12 cells were 
treated with 2.5S NGF (Boehringer Mannheim), EGF (Collaborative), 
recombinant bovine bFGF (kindly provided by Dr. A. Baird, Whittier 
Institute), K-252a (generous gift of G. Gurof0, MTA (Sigma), and 
M L-9 (Sigma). Following treatment, PC 12 cells were rinsed three times 
with ice-cold phosphate-buffered saline and RNA was isolated as de- 
scribed below. 
2.2. RNA isolation and RNase protection analysis 
PC 12 cells were lysed, nuclei and cytosol fractionated by centrifuga- 
tion [19], and cytoplasmic RNA isolated [20]. Where indicated, total 
cellular RNA was isolated as described [21]. RNase protection analysis 
was performed [20] using antisense VGF exon 3 and cyclophilin probes 
[11] to quantify cytoplasmic VGF and cyclophilin (internal control) 
mRNA levels, respectively. Samples containing 10 pg of total RNA 
were analyzed in duplicate or triplicate, and protected RNA fragments 
were resolved on nondenaturing 5% polyacrylamide g ls using MspI- 
digested pBR322 DNA as molecular size markers. After autoradio- 
graphic exposure, bands were quantified by scintillation counting or 
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with a Molecular Dynamics Phosphoimager, and the results expressed 
as relative level of VGF mRNA, computed as the ratio of radioactivity 
of the treated sample to that of the control (treatment/control), with 
control defined as 1. 
2.3. Northern blot analysis 
RNA samples (10/lg per lane) were electrophoresed through 0.8% 
agarose gels containing 2.2 M formaldehyde, 40 mM morpholine- 
propanesulfonic a id (MOPS) buffer (pH 7), 10 mM sodium acetate 
and 1 mM EDTA, and then electrophoretically transferred to nylon 
membranes and hybridized to 3Zp-labeled antisense RNA probes (10  6 
cpm/ml hybridization buffer containing 5 × SSC, 1 × Denhardt's solu- 
tion, 20 mM sodium phosphate (pH 6.8), 50% formamide, 0.5% SDS 
and 0.1 mg/ml denatured salmon sperm DNA) at 68°C for 16-24 h. 
RNA probes were synthesized from the following linearized cDNA 
clones: VGF8a [13] and plB15 (cyclophilin) [22]. Blots were washed 
twice in 0.1 × SSC, 0.1% SDS for 20 min at 68°C, and then subjected 
to autoradiography. 
2.4. Antibody preparation and Western blot analysis 
Rabbit polyclonal antibodies were prepared against a VGF(amino 
acids 78 340)-trpE fusion protein. An IgG fraction was affinity-puri- 
fied sequentially on trpE and VGF-trpE columns, essentially as de- 
scribed [23]. Crude cytoplasmic cell extracts were isolated by three rapid 
freeze thaw cycles followed by centrifugation at 16,000 × g for 15 min. 
Whole cell extracts were obtained following lysis in 2 × sample buffer 
[24]. Samples containing equal amounts of protein, and molecular size 
standards of 97.4, 66.2, 45, 31, 21.5 and 14.4 kDa (BRL) were co- 
electrophoresed on 10% SDS-polyacrylamide gels and then transferred 
to nitrocellulose. Protein transfer and loading were confirmed by stain- 
ing filters with 0.2% Ponceau red in 3% trichloroacetic a id. Western 
blots were incubated with affinity purified anti-VGF IgG (h 1,000) and 
were developed using ECL reagents (Amersham). 
3. Results and discussion 
3.1. NGF and bFGF induce VGF mRNA levels in protein kinase 
A-deficient cells 
Treatment of PC12 cells with cAMP analogs induces VGF 
mRNA levels by 2 3-fold [11,14] (Fig. I, panel A). The presence 
of a CRE consensus sequence in the vgf promoter [11] 
prompted us to investigate whether there was a requirement for 
protein kinase A (PKA) in the induction of VGF mRNA by 
NGF and bFGF. We employed a PC12-derived cell line (A126 
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Fig. 1. NGF and bFGF induce VGF mRNA in protein kinase A- 
deficient cells. Parental PCI2 cells (panel A) and A-kinase deficient 
PC12 derivative A126-1B2 cells (panel B) were incubated for the indi- 
cated lengths of time (h) with I00 ng/ml NGF, 100 ng/ml bFGF or 1 
mM dbcAMP. Total RNA (10 /.tg/lane) was subjected to Northern 
analysis and the blot was hybridized to an antisense VGF riboprobe, 
autoradiographed, rehybridized to an antisense cycophilin riboprobe, 
and reautoradiographed. Portions of the autoradiograms are shown 
and the positions of the VGF and cyclophilin mRNAs are designated 
by the arrows. 
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Fig. 2. K-252a and MTA block induction of vgf gene expression by 
NGF. PC12 cells were pretreated for 1 h in growth media alone (con- 
trol) or in media supplemented with 200 ,uM K-252a, 3 mM MTA or 
100/IM ML-9, after which the cultures were incubated for 3.25 h with 
no further additions or with either 100 ng/ml NGF or 3 ng/ml EGF 
added. RNase protection analysis was carried out and the bands corre- 
sponding to the fragments protected by the radiolabeled VGF (solid 
arrow) and cyclophilin (open arrow; internal control) antisense probes 
were quantified and results expressed as relative level of VGF mRNA. 
RNA was prepared from replicate plates and samples were assayed in 
duplicate; each bar is the mean + S.E.M. (n = 4). 
1B2) which is deficient in PKA activity [25]; in these cells the 
CRE-CAT fusion gene is not inducible by cAMP elevation [26]. 
As expected, treatment of A126-1B2 cells with N6,2'-O-dibu - 
tyryladenosine 3': 5'-cyclic monophosphate (dbcAMP) did not 
induce VGF mRNA (Fig. 1, panel B). In contrast, treatment 
of these cells with NGF or bFGF  resulted in a level of VGF 
mRNA induction which was comparable to that obtained in the 
parental PC12 cells (Fig. 1, compare panels A and B), suggest- 
ing that these growth factors induce vgf gene expression pre- 
dominantly through PKA-independent pathways. Deletion 
analysis has suggested that two regions within the vgfpromoter, 
overlapping the CRE and the CCAAT elements, are involved 
in NGF-induction [17,27]. It would therefore appear that dis- 
tinct mechanisms and possibly different ransactivating factors 
regulate vgf gene expression in cAMP-stimulated and NGF-  
treated PC12 cells. In fact, c-fos expression has been shown to 
be induced by growth factors and by cAMP analogs through 
pathways that interact with different regulatory elements [28]. 
3.2. VGF mRNA induction by NGF is prevented by K-252a and 
the methylase inhibitor MTA 
K-252a specifically blocks all of the biological actions of 
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Fig. 3. Induction ofVGF mRNA and polypeptide is blocked in NGF-treated PCl2nnr5 cells expressing Trk Y490/Y785F but not in those xpressing 
Trk Y490F or Trk Y785F. Untreated PC12 cells and PC12nnr5 cells, stably transfected with Trk (line T14), Trk Y490F (line 490.6), Trk Y785F 
(line 785.24) or Trk Y490F/Y785F (line 490/785.14), or those treated with 50 ng/ml NGF for 1, 3, or 6 h, were subjected toRNase protection analysis. 
RNA samples were assayed induplicate and fragments protected by the radiolabeled VGF (solid arrow) and cyclophilin (open arrow) antisense probes 
were quantified and the results expressed inpanel B as relative level of VGF mRNA + S.E.M. In panel C, samples containing equal amounts of 
protein, isolated from whole cell extracts of 785.24, 785.11 and 490/785.14 cells and crude cytoplasmic fractions of PC12, T14 and 490.6 cells were 
subjected toSDS-PAGE and Western blotting with anti-VGF IgG. After ECL development, blots were exposed to XAR-5 film for 5 10 s. The VGF 
polypeptide, a doublet migrating with an apparent size of ~85-90 kDa, is indicated by the arrowheads. 
NGF but not other factors on PC12 cells [29] and inhibits the 
tyrosine kinase catalytic activity of Trk [30], the high affinity 
NGF-receptor [4,5]. PC12 cells were pretreated for 1 h with 200 
pM K-252a and were then treated with either NGF or EGF and 
K-252a for 3.25 h. VGF mRNA levels, determined by RNase 
protection analysis [14], have been normalized to the unregu- 
lated mRNA cyclophilin to control for differences in input 
RNA amount and gel loading. K-252a treatment inhibited 
VGF induction in the presence of NGF by 86% (Fig. 2). The 
methylase inhibitor MTA, which blocks the neuronal differen- 
tiation of PC12 cells in the presence of NGF [19,31], reduced 
VGF mRNA induction by 74% when applied to NGF-treated 
cells (Fig. 2). For comparison, treatment with the myosin light 
chain kinase inhibitor ML-9 [32] had no significant effect on 
VGF mRNA induction by NGF, nor did any of the inhibitors 
affect the induction of VGF mRNA levels by EGF (Fig. 2). 
3.3. VGF induction following NGF-treatment is reduced in 
PC12nnr5 cells expressing Trk with mutations in both Y490 
and Y785 
To determine the relative contributions of specific signal 
transduction pathways downstream of the NGF receptor to 
VGF induction, we examined regulation of VGF mRNA levels 
in PC12nnr5 cells transfected with wild type Trk or with Trk 
containing mutations (phenylalanine fortyrosine substitutions) 
in Y490, in Y785 or in both Y490 and Y785 [33]. PC12nnr5 cells 
lack Trk and fail to respond to NGF; expression of Trk restores 
NGF responsiveness in these cells [6,34]. The Y490 of Trk 
mediates association with SHC [33,35] while the Y785 of Trk 
is required for interaction with PLC-x1 [33,36]. To control for 
possible differences in the kinetics or level of VGF mRNA 
induction in PC12nnr5-derived lines which might not be di- 
rectly related to mutations inTrk, VGF mRNA levels in EGF- 
treated cells were also measured, and were found to be similar 
to EGF-treated PC12 cells (data not shown). As is shown in 
Fig. 3, panel A, mutation of either Y490 (line 490.6) or Y785 
(line 785.24; similar results for line 785.11 not shown) did not 
substantially alter the magnitude or kinetics of VGF mRNA 
induction in NGF-treated cells compared to either T14 
(PCl2nnr5 cells transfected with Trk) or PC12 cells. VGF 
mRNA induction in NGF-treated cells expressing Trk with 
mutations in both Y490 and Y785 was not detectable (line 
4901785.14; comparable results for 490/785.21 not shown). 
Quantitation ofthese results (panel B) is representative of three 
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Fig. 4. Effect of treatment with 6-TG, 2-AP and 6-MMPR on the 
induction of VGF mRNA levels. VGF and cyclophilin mRNA levels 
were determined by RNase protection analysis and results expressed as
relative level of VGF mRNA. Samples, containing l0/tg of total RNA 
[21], were assayed in triplicate; ach bar is the mean + S.E.M. In panel 
A, untreated PC12 cells (control) and those grown for 0.5, 1, 2, and 4 
h in the presence ofNGF, NGF + 6-TG, NGF + 2-AP, 6-TG or 2-AP 
were analyzed. In panel B, VGF mRNA levels were quantified in 
untreated PCI2 cells (control) and cells treated for 6 h with NGF, 6 h 
with 2-AP + NGF, 1 h 2-AP + NGF following the previous addition 
of NGF for 5 h, 6 h with 6-TG + NGF, and for 10 min with NGF alone 
followed by the addition of 6-TG + NGF for 6 h. In panel C, VGF 
mRNA levels were quantified in untreated (control) and 5 h NGF- 
treated PCI2 cells, all in the presence or absence of 10 or 100 pM 
6-MMPR. 
additional experiments; induction of VGF mRNA in T14 cells 
was not quantified because basal levels were below detection. 
Examination of VGF protein expression in untreated and 
NGF-treated cells by Western analysis confirmed these obser- 
vations (panel C). VGF polypeptide induction in response to 
NGF-treatment was eliminated in the 4901785.14 line, but was 
still found in the 490.6, 785.11, and 785.24 lines, as well as in 
PC12 and TI4 cells containing wild type Trk. 
Regulation of vgf gene expression by NGF is therefore dis- 
tinct from that of peripherin which is abolished by mutation of 
Y785 [37]. Since cells expressing Trk with the Y785 mutation 
contain tyrosine phosphorylated SHC and Grb2 in the absence 
of NGF [33] and have levels ofVGF mRNA that are compara- 
ble to untreated PC12 cells, activation of SHC and Grb2 alone 
is not sufficient o trigger VGF mRNA induction. In cells 
expressing Trk Y490/Y785, in which both the PLC-~,I and SHC 
association sites are mutated, VGF mRNA and polypeptide 
levels did not significantly change in response to NGF-treat- 
ment, indicating that activation of c-Ras, ERK 1 and possibly 
additional molecules is required for vgf gene induction by 
NGF. Since comparable induction of VGF mRNA levels was 
observed in each of the PC12, 490.6 and 785.24 cell lines, stim- 
ulation of the PLC-71 or the SHC pathway alone, or possibly 
additional signaling pathways that might be activated through 
association with either the PLC-?'I or the SHC binding sites of 
Trk, is sufficient to maximally induce VGF expression. 
3.4. Partial inhibition of the induction of VGF mRNA in the 
presence of purine analogs 
Since purine analogs inhibit a number of the specific actions 
of NGF on PC12 cells, such as neurite regeneration a d orni- 
thine decarboxylase (ODC) induction, while differentially 
blocking others that include c-fos, c-jun, TIS1 and TIS11 induc- 
tion [8, 9, 38, 39], we tested their effect on the levels of VGF 
mRNA in naive and NGF-treated cells. Purine analogs up- 
press several specific phosphorylation activities, and block in 
vitro activity of the NGF-stimulated kinase designated protein 
kinase N (PKN) at the concentrations employed [8,10,18,39] . 
As is shown in Fig. 4, panel A, 2-AP (10 raM) partially blocked 
the induction of VGF mRNA levels in PC 12 cells treated with 
NGF for 1 and 2 h, but did not significantly inhibit induction 
after 4~6 h of NGF treatment (P < 0.05, one factor ANOVA, 
Scheffe F-test). Treatment with 6-TG (0.5 mM) resulted in a 
partial but significant block of VGF mRNA induction by NGF 
in cultures incubated for 1-4 h (P < 0.05, one factor ANOVA, 
Scheffe F-test). No significant difference in VGF mRNA levels 
was observed among cultures treated with NGF, NGF + 2-AP, 
and NGF + 6-TG for 6 h (Fig. 4, panels A and B). Prior analysis 
of these same RNA samples demonstrated that the induction 
of ODC by a 6 h treatment with NGF was blocked if the 2-AP 
was present for the last hour of NGF treatment [18]. Further- 
more, a 10 min preincubation with NGF was sufficient o 
abolish the inhibition by 6-TG of NGF-dependent ODC induc- 
tion [18]. Neither of these treatments were found to alter VGF 
mRNA levels (Fig. 4, panel B). In comparison to NGF treat- 
ment, treatment with NGF + 10 or 100 pM 6-MMPR led to 
significant 27% and 48% decreases, respectively, in VGF 
mRNA levels (P < 0.05, one factor ANOVA, Scheffe F-test) 
(Fig. 4, panel C). Induction ofODC mRNA by NGF, measured 
in these same RNA samples, was inhibited 86-93% by 6- 
MMPR [39]. Previous analysis revealed that the concentrations 
of 6-MMPR, 2-AP and 6-TG employed were sufficient to in- 
hibit PKN kinase activity by 85-90% [8,18,39,40]. 
In addition to strongly inhibiting PKN, 2-AP inhibits Ca2+/ 
calmodulin-dependent ki ase I and several other kinases in- 
cluding the ERK/MAP kinases [7,39,41,42], while reports differ 
as to whether 6-TG inhibits [7] or does not inhibit at all [41,42] 
ERK/MAP kinase activity. Finally, 6-MMPR appears to very 
selectively inhibit PKN but not MAP kinase activity [39] (C. 
Volont& unpublished data). Partial blockade of VGF mRNA 
induction is unlikely to be due to partial inhibition of kinase 
activity since (i) these concentrations u ed under these condi- 
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tions have been shown to inhibit PKN activity [8,10,39] and (ii) 
some of these RNA samples have been previously analyzed and 
complete inhibition of ornithine decarboxylase induction by 
2-AP and 6-MMPR was found [39,40]. Partial blockade by 
2-AP and 6-TG of the induction of transin mRNA in NGF-  
treated PC12 cells has been observed, though time course stud- 
ies were not performed to investigate whether the inhibitors 
delay rather than reduce transin mRNA induction [43]. In fact, 
induction of TIS1 (also designated NGFI-B or nur77) mRNA 
by NGF is delayed by 2-AP [38]. The finding that PKN is not 
activated by NGF in PC12 cells expressing dominant-negative 
v-Ras (C. Volont6 and L.A. Greene, unpublished data) is con- 
sistent with a role for PKN in the regulation of VGF expres- 
sion. PKN may be one component in the pathway that controls 
vgf gene induction, however other regulatory pathways must 
also contribute to this induction. In some cases, activation of 
these alternative pathways may lead to compensatory increases 
in VGF mRNA levels when PKN activity is blocked. 
Acknowledgments: We thank M. Baybis for technical assistance, R. 
Woolley for photography, and Dr.'s R. Metz and E.B. Ziff for provid- 
ing pATH22. This work was supported by NIH Grants AG10676 and 
GM41227 (S.R.J.S.), a Sigma Tau Foundation Fellowship Award to 
C.V. and a Hoffman-La Roche Fellowship to G.D.S.R.J. Salton is a 
Pew Scholar in the Biomedical Sciences. 
References 
[1] Greene, L.A. and Tischler, A.S. (1976) Proc. Natl. Acad. Sci. USA 
73, 2424-2428. 
[2] Maher, EA. (1988) Proc. Natl. Acad. Sci. USA 85, 6788~791. 
[3] Halegoua, S., Armstrong, R.C. and Kremer, N.E. (1991) Micro- 
biol. Immunol. 165, 119-170. 
[4] Kaplan, D.R., Hempstead, B.L., Martin-Zanca, D., Chao, M.V. 
and Parada, L.F. (1991) Science 252, 554-558. 
[5] Klein, R., Jing, S., Nanduri, V., O'Rourke, E. and Barbacid, M. 
(1991) Cell 65, 189-197. 
[6] Loeb, D.M., Maragos, J., Martin-Zanca, D., Chao, M.V., Parada, 
L.F. and Greene, L.A. (1991) Cell 66, 961-966. 
[7] Qiu, M.-S. and Green, S.H. (1992) Neuron 9, 705-717. 
[8] Volont6, C., Rukenstein, A., Loeb, D.M. and Greene, L.A. (1989) 
J. Cell Biol. 109, 2395-2403. 
[9] Greene, L.A., Volont6, C. and Chalazonitis, A. (1990) J. Neurosci. 
10, 1479-1485. 
[10] Volont6, C. and Greene, L.A. (1992) J. Biol. Chem. 267, 21663- 
21670. 
[11] Salton, S.R.J., Fischberg, D.J. and Dong, K.-W. (1991) Mol. Cell. 
Biol. 11, 2335-2349. 
[12] Bartel, D.P., Sheng, M., Lau, L.F. and Greenberg, M.E. (1989) 
Genes Dev. 3, 304-313. 
[13] Levi, A., Eldridge, J.D. and Paterson, B.M. (1985) Science 229, 
393-395. 
[14] Salton, S.R.J. (1991) J. Neurochem. 57, 991-996. 
[15] D'Arcangelo, G. and Halegoua, S. (1993) Mol. Cell. Biol. 13, 
3146-3155. 
[16] Baybis, M.B. and Salton, S.R.J. (1992) FEBS Lett. 308, 202-206. 
[17] Possenti, R., Di Rocco, G., Nasi, S. and Levi, A. (1992)Proc. Natl. 
Acad. Sci. USA 89, 3815-3819. 
[18] Volont6, C. and Greene, L.A. (1990) J. Biol. Chem. 265, 11050- 
11055. 
[19] Greenberg, M.E., Greene, L.A. and Ziff, E.B. (1985) J. Biol. 
Chem. 260, 14101-14110. 
[20] Salton, S.R., Blum, M., Jonassen, J.A., Clayton, R.N. and 
Roberts, J.L. (1988) Mol. Endocrinol. 2, 1033 1042. 
[21] Cathala, G., Savouret, J.-F., Mendez, B., West, B.L., Karin, M., 
Martial, J.A. and Baxter, J.D. (1983) DNA 2, 329-335. 
[22] Danielson, EE., Forss-Petter, S., Brow, M.A., Calavetta, L., 
Douglass, J., Milner, R.J. and Sutcliffe, J.G. (1988) DNA 7, 261- 
267. 
[23] Gorham, J.D., Baker, H., Kegler, D. and Ziff E.B. (1990) Dev. 
Brain Res. 57, 235-248. 
[24] Laemmli, U.K. (1970) Nature 227, 680-685. 
[25] Van Busirk, R., Corcoran, T. and Wagner, J.A. (1985) Mol. Cell. 
Biol. 5, 1984-1992. 
[26] Montminy, M.R., Sevarino, K.A., Wagner, J.A., Mandel, G. and 
Goodman, R.H. (1986) Proc. Natl. Acad. Sci. USA 83, 6682-6686. 
[27] Hawley, R.J., Scheibe, R.J. and Wagner, J.A. (1992) J. Neurosci. 
12, 2573 2581. 
[28] Sheng, M., McFadden, G. and Greenberg, M.E. (1990) Neuron 
4, 571-582. 
[29] Koizumi, S., Contreras, M.L., Matsuda, Y., Hama, T., Lazarovici, 
P. and Guroff, G. (1988) J. Neurosci. 8, 715 721. 
[30] Berg, M.M., Sternberg, D.W., Parada, L.F. and Chao, M.V. 
(1992) J. Biol. Chem. 267, 13-16. 
[31] Seeley, EJ., Rukenstein, A., Connolly, J.L. and Greene, L.A. 
(1984) J. Cell Biol. 98, 4174-26. 
[32] Nakanishi, S., Yamada, K., Iwahashi, K., Kuroda, K. and Kase, 
H. (1990) Mol. Pharmacol. 37, 482~,88. 
[33] Stephens, R.M., Loeb, D.M., Copeland, T.D., Pawson, T., 
Greene, L.A. and Kaplan, D. (1994) Neuron 12, 691-705. 
[34] Green, S.H. and Greene, L.A. (1986) J. Biol. Chem. 261, 15316- 
15326. 
[35] Obermeier, A., Lammers, R., Weismiiller, K.-H., Jung, G., 
Schlessinger, J. and Ullrich, A. (1993) J. Biol. Chem. 268, 22963- 
22966. 
[36] Obermeier, A., Halfter, H., Wiesmiiller, K.-H., Jung, J., 
Schlessinger, J. and Ullrich, A. (1993) EMBO J. 12, 933-941. 
[37] Loeb, D.M., Stephens, R.M., Copeland, T., Kaplan, D.R. and 
Greene, L.A. (1994) J. Biol. Chem. 269, 8901 8910. 
[38] Batistatou, A., Volont6, C. and Greene, L.A. (1992) Mol. Biol. 
Cell 3, 363-371. 
[39] Volont6, C. and Greene, L.A. (1992) J. Neurochem. 58, 700-708. 
[40] Volont6, C. and Greene, L.A. (1990) Growth Factors 2, 321 331. 
[41] Tsao, H., Aletta, J.M. and Greene, L.A. (1990) J. Biol. Chem. 265, 
15471 15480. 
[42] Tsao, H. and Greene, L.A. (1991) J. Biol. Chem. 266, 12981- 
12988. 
[43] Machida, C,M., Scott, J.D. and Ciment, G. (1991) J. Cell Biol. 114, 
1037-1048. 
